TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class.

GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing a $2 billion plus licensing agreement with iTeos Therapeutics for ...

Find the latest iTeos Therapeutics, Inc. (ITOS) stock quote, history, news and other vital information to help you with your stock trading and investing.